Plain-English translation of NCT07691970 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This is a rollover study for people who participated in an earlier clinical trial testing and experienced real benefits from the treatment. The study lets you continue receiving after your previous study ends, while the research team keeps a close watch on how safe and well-tolerated the medication is over the long term.
When patients in a clinical trial are doing well on a new medication and their disease is improving, suddenly stopping that treatment at the end of the trial can be harmful. This study exists to bridge that gap—letting people continue this treatment while researchers gather more safety information.
You likely qualify if…
You likely don't qualify if…
You will continue to receive in the same way you received it during your previous study—likely through regular infusions or injections at clinic visits. Throughout your participation, the study team will monitor you for any side effects and assess how well the medication continues to work for you. You will stay in the study until either you or your doctor decide to stop, or until you meet other criteria for ending participation, with safety follow-up continuing for up to 12 weeks after your last dose.
AI-generated summary from trial data · Oct 5, 2026 · Not medical advice
United States